Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis.

Cancers (Basel) · 2022 · PMC9817514 · PMID 36612035

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The trial by Chen et al., 2015 [ 34 ] showed a trend toward improved PFS was observed, but the addition of cetuximab did not significantly improve the ORR of GEMOX chemotherapy in advanced BTC, and KRAS mutations did not affect the trend in ORR and PFS differences between C-GEMOX and GEMOX.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.